ethyl 2-(6-methoxy-2,3-dihydro-1H-inden-1-ylidene)acetate | 36158-93-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: ethyl 2-(6-methoxy-2,3-dihydro-1H-inden-1-ylidene)acetate
• 英文别名: (6-methoxy-indan-1-ylidene)-acetic acid ethyl ester；ethyl 2-(6-methoxy-2,3-dihydroinden-1-ylidene)acetate
• CAS: 36158-93-7
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: MJCOAIWDYDUTED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(6-methoxy-2,3-dihydro-1H-inden-1-ylidene)acetate 在 5% Pd on active carbon lithium aluminium tetrahydride 、 氢气 、 三溴化磷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.25h， 生成 1-(2-bromoethyl)-2,3-dihydro-6-methoxy-1H-indene
  参考文献：
  名称：

  Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists

  摘要：

  We synthesized a novel series of benzocycloalkene derivatives and evaluated their binding affinities to melatonin receptors. To control the spatial position of the amide group, one of the important pharmacophores, we incorporated an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) at position 1. The indan derivatives with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT, site), while compounds with the R-configuration showed little potential. Our next attempt was to investigate the most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT, receptor. The introduction of a methyl group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-8d [(S)-N-[2-(2,3-dihydro-6-methoxy-1H-inden-1-yl)ethyl]propionamide], which had high affinity for the human MT3 receptor (K-i = 0.041 nM) but no significant affinity for the hamster MT3 receptor (K-i = 3570 nM). In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]-alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established.

  DOI：

  10.1021/jm020114g
• 作为产物：
  描述：

  6-甲氧基-1-茚酮 在 对甲苯磺酸 、 calcium chloride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 18.33h， 生成 ethyl 2-(5-methoxy-1H-inden-3-yl)acetate 、 ethyl 2-(6-methoxy-2,3-dihydro-1H-inden-1-ylidene)acetate
  参考文献：
  名称：

  Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2′-Des-methyl-sulindac Sulfide Scaffold

  摘要：

  Prostaglandins (PGs) are powerful lipid mediators in many physiological and pathophysiological responses. They are produced by oxidation of arachidonic acid (AA) by cyclo- oxygenases (COX-1 and COX-2) followed by metabolism of endoperoidde intermediates by terminal PG synthases. PG biosynthesis is inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs). Specific inhibition of COX-2 has been extensively investigated, but relatively few COX-1-selective inhibitors have been described. Recent reports of a possible contribution of COX-1 in analgesia, neuroinflammation, or carcinogenesis suggest that COX-1 is a potential therapeutic target. We designed, synthesized, and evaluated a series of (E)-2'-des-methyl-sulindac sulfide (E-DMSS) analogues for inhibition of COX-1. Several potent and selective inhibitors were discovered, and the most promising compounds were active against COX-1 in intact ovarian carcinoma cells (OVCAR-3). The compounds inhibited tumor cell proliferation but only at concentrations >100-fold higher than the concentrations that inhibit COX-1 activity. E-DMSS analogues may be useful probes of COX-1 biology in vivo and promising leads for COX-1-targeted therapeutic agents.

  DOI：

  10.1021/jm201528b

文献信息

• Synthesis of novel molecular probes inspired by harringtonolide
  作者：Vinayak Hegde、Marc Campitelli、Ronald J. Quinn、David Camp

  DOI：10.1039/c1ob05299c

  日期：——

  A novel harringtonolide-inspired scaffold containing a cycloheptatriene ring and two fused cyclopentane rings has been synthesised from simple starting materials. The scaffold, containing a similar substitution pattern and relative stereochemistry to the complex diterpenoid, has been enumerated into a small library of derivatives. One of these library members has been converted into a sub-library of substituted triazoles using copper-catalysed azide-alkyne cycloaddition (click) chemistry. The scaffold may be useful in drug discovery or in the preparation of additional molecular probes for chemical biology.

  一个受哈灵顿烯启发的新型骨架，包含一个环七烯环和两个融合的环戊烷环，已从简单的起始材料合成。该骨架具有与复杂的二萜类相似的取代模式和相对立体化学，并已被扩展为一小型衍生物库。这个库中的一个成员已通过铜催化的叠氮-三键环加成（点击）化学转化为一个取代类三唑的子库。该骨架可能在药物发现中或用于制备额外的化学生物学分子探针方面具有应用潜力。
• Sulfonyl-substituted bicyclic compounds as modulators of PPAR
  申请人：Noble A. Stewart

  公开号：US20060167012A1

  公开（公告）日：2006-07-27

  Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

  本发明揭示了作为过氧化物酶体增殖物激活受体的调节剂的化合物，包括这些化合物的制药组合物以及使用它们治疗疾病的方法。
• SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
  申请人：Noble Stewart A.

  公开号：US20090227599A1

  公开（公告）日：2009-09-10

  Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

  本发明揭示了化合物作为过氧化物酶体增殖物活化受体的调节剂，以及包含该化合物的制药组合物和使用该化合物治疗疾病的方法。
• Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists
  作者：Kohji Fukatsu、Osamu Uchikawa、Mitsuru Kawada、Toru Yamano、Masayuki Yamashita、Koki Kato、Keisuke Hirai、Shuji Hinuma、Masaomi Miyamoto、Shigenori Ohkawa

  DOI：10.1021/jm020114g

  日期：2002.9.1

  We synthesized a novel series of benzocycloalkene derivatives and evaluated their binding affinities to melatonin receptors. To control the spatial position of the amide group, one of the important pharmacophores, we incorporated an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) at position 1. The indan derivatives with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT, site), while compounds with the R-configuration showed little potential. Our next attempt was to investigate the most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT, receptor. The introduction of a methyl group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-8d [(S)-N-[2-(2,3-dihydro-6-methoxy-1H-inden-1-yl)ethyl]propionamide], which had high affinity for the human MT3 receptor (K-i = 0.041 nM) but no significant affinity for the hamster MT3 receptor (K-i = 3570 nM). In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]-alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established.
• Cyclooxygenase-1-Selective Inhibitors Based on the (<i>E</i>)-2′-<i>Des</i>-methyl-sulindac Sulfide Scaffold
  作者：Andy J. Liedtke、Brenda C. Crews、Cristina M. Daniel、Anna L. Blobaum、Philip J. Kingsley、Kebreab Ghebreselasie、Lawrence J. Marnett

  DOI：10.1021/jm201528b

  日期：2012.3.8

  Prostaglandins (PGs) are powerful lipid mediators in many physiological and pathophysiological responses. They are produced by oxidation of arachidonic acid (AA) by cyclo- oxygenases (COX-1 and COX-2) followed by metabolism of endoperoidde intermediates by terminal PG synthases. PG biosynthesis is inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs). Specific inhibition of COX-2 has been extensively investigated, but relatively few COX-1-selective inhibitors have been described. Recent reports of a possible contribution of COX-1 in analgesia, neuroinflammation, or carcinogenesis suggest that COX-1 is a potential therapeutic target. We designed, synthesized, and evaluated a series of (E)-2'-des-methyl-sulindac sulfide (E-DMSS) analogues for inhibition of COX-1. Several potent and selective inhibitors were discovered, and the most promising compounds were active against COX-1 in intact ovarian carcinoma cells (OVCAR-3). The compounds inhibited tumor cell proliferation but only at concentrations >100-fold higher than the concentrations that inhibit COX-1 activity. E-DMSS analogues may be useful probes of COX-1 biology in vivo and promising leads for COX-1-targeted therapeutic agents.